Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation

Stock Track

07/31

Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.

The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.

Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1199189721"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199189721\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199189721?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199189721","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation","media":"Stock Track","content":"<p>Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.</p><p>The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.</p><p>Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-07-31 02:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.</p><p>The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.</p><p>Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1199189721","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199189721","pubTimestamp":1785437464,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票跟踪 | 埃博拉疫苗试验启动，Moderna 盘中飙升 5.01%，盈利预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}